version: 2.0







In order to use this report template, you should have the latest Acrobat Reader version available (at least Acrobat Reader version 8.1.5).

You can check the version in the "Help" menu under "About Acrobat Reader" item. If you don't have a correct version, please download it here: http://www.adobe.com/products/acrobat/readstep2.html

For technical questions related to the use of this form, please send an email to the following address: SANCO-SARE@ec.europa.eu

For more information please read our "Privacy statement" at the end of this document.

Instruction for completing the report template:

- 1) This report template should be filled in according to the definitions and recommendations provided in the "Common approach for definitions of reportable serious adverse events and reactions as laid down in the Blood Directive 2002/98/EC and Commission Directive 2005/61/EC Version 2 (2009)".
- References to the relevant sections of the Common approach document are made on each question of this report template. Please provide as much information as possible, in addition to those required by fields marked with an asterisk (*) which are mandatory. Should you need clarifications on some of the information requested, please contact SANCO-SARE@ec.europa.eu.
- 2) Absence of data in one field means "0" or "Non Available". Therefore, please just fill in the tables when you have data or cases to report.
- 3) To verify your data entry while filling your form, you can use the "verify form" button at the top of each page.
- 4) When you have finished filling the form, please verify that your internet connection is active and then click on the submit notification button below. If the form is properly filled, the notification will be submitted to the server and a Submission number will appear in the corresponding field. Once you have received the Submission number, save the form on your computer for your records.
- 5) If the form is not properly filled, an alert box will appear indicating the number of incorrect fields. Please check your form again and try to re-submit it according to step 4). Should you still have any difficulties, please contact SANCO-SARE@ec.europa.eu.
- 6) If you receive an error message, please send its reference to SANCO-SARE@ec.europa.eu in order to properly manage it.

Submission number

1251472346710-608

version: 2.0

Portugal	

This data collection refers to the period 1st January 2008 - 31 December 2008 included (See point 1.1 of the Common approach version 2)

Annual notification for Serious Adverse REACTION(S)

Serious adverse reactions in donor of blood and blood comp (See point 2.1 of the common approach version 2)	ponents :
Comment:	
Annual notification for serious adverse reaction(s) related Red blood cells	to*:
Number of units issued *: 462,442	Total number of units issued with a given number of blood components (See point 2.2.1 of the Common approach version 2)
Number of recipients transfused (if available): 54,546	Total number of recipients transfused with a given number of blood components. (See section 2.2.2 of the common approach version 2)
Number of units tranfused (if available): 278,233	Total number of blood components (units) transfused over the reporting period. (See section 2.2.3 of the common approach version 2)
A: Number of confirmed reports of serious adverse reactions related to ble safety of the blood/blood component B: Number of confirmed reports of serious adverse reactions related to ble safety of the blood/blood component	

(See section 2.3 of the common approach version 2)

Imputability level aft Serious Adver	er confirmation of se Reaction(s)		not assessable	Level 0	Level 1	Lev	el 2	Lev	el 3	Total
						Α	В	Α	В	
Immunological Haemolysis	Due to ABO incompatibility	Total no death								0

version: 2.0

		Total deaths								0
	Due to other allo- antibody	Total no death								0
		Total deaths								0
			not assessable	Level 0	Level 1	Leve	el 2	Leve	el 3	Total
						Α	В	A	В	
Non-immunological Haemolysis		Total no death								0
		Total deaths								0
			not assessable	Level 0	Level 1	Lev	el 2	Lev	el 3	Total
						Α	В	Α	В	
Transfusion-transmitted bacterial infection		Total no death								0
		Total deaths								0
			not assessable	Level 0	Level 1	Lev	el 2	Lev	el 3	Total
						Α	В	Α	В	
Anaphylaxis/hypersensitivity		Total no death				1				1
		Total deaths								0
			not assessable	Level 0	Level 1	Lev	el 2	Lev	el 3	Total
						Α	В	Α	В	
Transfusion related acute lung injury		Total no death			1	1				2
		Total deaths								0
			not assessable	Level 0	Level 1	Lev	el 2	Lev	el 3	Total
						Α	В	Α	В	
Transfusion-transmitted viral infection	HBV	Total no death								0
		Total deaths								0
	HCV	Total no death								0
		Total deaths								0
	HIV-1/2	Total no death								0
		Total deaths								0

version: 2.0

		not assessable	Level 0	Level 1	Lev	el 2	Lev	el 3	Total
					Α	В	Α	В	
Transfusion-transmitted parasitical infection	Total no death								0
	Total deaths								0

Add other type of Transfusion-transmitted parasital infection

			not assessable	Level 0	Level 1	Lev	el 2	Lev	Total	
					A	В	A	В		
Post-transfusion purpura Total no death									0	
		Total deaths								0
			not assessable	Level 0	Level 1	Lev	el 2	Lev	el 3	Total
						Α	В	Α	В	
Graft versus host disease	Graft versus host disease Total no death									0
		Total deaths								0

Add other serious adverse reaction(s)

Total number of	f Serious	Adverses	Reactions	for	this	type of blood	
component:							

3

Comments:

version: 2.0

69,734

Annual notification for serious adverse reaction(s) rela Platelets	ted to*:
Number of units issued * : 144,244	Total number of units issued with a given number of blood components (See point 2.2.1 of the Common approach version 2)
Number of recipients transfused (if available): 5,602	Total number of recipients transfused with a given number of blood components. (See section 2.2.2 of the common approach version 2)
Number of units tranfused (if available):	

A: Number of confirmed reports of serious adverse reactions related to blood or blood components which are not attributable to the quality and

reporting period.

Total number of blood components (units) transfused over the

(See section 2.2.3 of the common approach version 2)

safety of the blood/blood component

B. Number of confirmed reports of serious adverse reactions related to blood or blood components which are attributable to the quality and safety of the blood/blood component.

(See section 2.3 of the common approach version 2)

Imputability level aft Serious Adver	er confirmation of se Reaction(s)	the	not assessable	Level 0	Level 1	Lev	el 2	Lev	el 3	Total
						Α	В	Α	В	
Immunological Haemolysis	Due to ABO incompatibility	Total no death								0
		Total deaths								0
	Due to other allo- antibody	Total no death								0
		Total deaths								0
			not assessable	Level 0	Level 1	Lev	el 2	Lev	el 3	Total
						Α	В	A	В	
Non-immunological Haemolysis		Total no death								0
		Total deaths								0
			not assessable	Level 0	Level 1	Lev	el 2	Lev	el 3	Total
						Α	В	A	В	
Transfusion-transmitted bacterial infection		Total no death								0
		Total deaths								0

version: 2.0

			not assessable	Level 0	Level 1	Lev	el 2	Lev	el 3	Total
						Α	В	Α	В	
Anaphylaxis/hypersensitivity		Total no death			1	1				2
		Total deaths								0
			not assessable	Level 0	Level 1	Lev	el 2	Lev	el 3	Total
						Α	В	Α	В	
Transfusion related acute lung injury		Total no death								0
		Total deaths								0
			not assessable	Level 0	Level 1	Lev	el 2	Lev	el 3	Total
						Α	В	Α	В	
Transfusion-transmitted viral infection	HBV	Total no death								0
		Total deaths								0
	HCV	Total no death								0
		Total deaths								0
	HIV-1/2	Total no death								0
		Total deaths								0

Add other type of Transfusion-transmitted viral infection

		not assessable	Level 0	Level 1	Lev	el 2	Leve	el 3	Total
					A	В	A	В	
Transfusion-transmitted parasitical infection	Total no death								0
	Total deaths								0

			not assessable	Level 0	Level 1	Level 2		Level 3		Total
						Α	В	A	В	
Post-transfusion purpura		Total no death								0
		Total deaths								0
			not assessable	Level 0	Level 1	Lev	el 2	Lev	el 3	Total

version: 2.0

			A	В	Α	В		
Graft versus host disease	Total no death						0	
	Total deaths						0	

Add other serious adverse reaction(s)

Total	number	of	Serious	Adverses	Reactions	for	this	type o	f blood
compo	onent :								

2			

Comments:

version: 2.0

9,831

Annual notification for serious adverse reaction(s) related Plasma	d to*:
Number of units issued *: 177,477	Total number of units issued with a given number of blood components (See point 2.2.1 of the Common approach version 2)
Number of recipients transfused (if available): 1,521	Total number of recipients transfused with a given number of blood components. (See section 2.2.2 of the common approach version 2)
Number of units tranfused (if available):	Total number of blood components (units) transfused over the

A: Number of confirmed reports of serious adverse reactions related to blood or blood components which are not attributable to the quality and safety of the blood/blood component

reporting period.

(See section 2.2.3 of the common approach version 2)

B: Number of confirmed reports of serious adverse reactions related to blood or blood components which are attributable to the quality and safety of the blood/blood component.

(See section 2.3 of the common approach version 2)

Imputability level aft Serious Adver	er confirmation of se Reaction(s)	the	not assessable	Level 0	Level 1	Lev	el 2	Lev	el 3	Total
						Α	В	Α	В	
Immunological Haemolysis	Due to ABO incompatibility	Total no death								0
		Total deaths								0
	Due to other allo- antibody	Total no death								0
		Total deaths								0
			not assessable	Level 0	Level 1	Lev	el 2	Lev	el 3	Total
						Α	В	A	В	
Non-immunological Haemolysis		Total no death								0
		Total deaths								0
			not assessable	Level 0	Level 1	Lev	el 2	Lev	el 3	Total
						Α	В	A	В	
Transfusion-transmitted bacterial infection		Total no death								0
		Total deaths								0

version: 2.0

			not assessable	Level 0	Level 1	Lev	el 2	Lev	el 3	Total
						Α	В	Α	В	
Anaphylaxis/hypersensitivity		Total no death								0
		Total deaths								0
			not assessable	Level 0	Level 1	Lev	el 2	Lev	el 3	Total
						Α	В	Α	В	
Transfusion related acute lung injury		Total no death								0
		Total deaths								0
			not assessable	Level 0	Level 1	Lev	el 2	Lev	el 3	Total
						Α	В	Α	В	
Transfusion-transmitted viral infection	HBV	Total no death								0
		Total deaths								0
	HCV	Total no death								0
		Total deaths								0
	HIV-1/2	Total no death								0
		Total deaths								0

Add other type of Transfusion-transmitted viral infection

		not assessable	Level 0	Level 1	Lev	el 2	Leve	el 3	Total
					A	В	A	В	
Transfusion-transmitted parasitical infection	Total no death								0
	Total deaths								0

		not assessable Level 0 Level 1		Level 2 Leve		el 3	Total		
					Α	В	A	В	
Post-transfusion purpura	Total no death								0
	Total deaths								0
		not assessable	Level 0	Level 1	Lev	el 2	Lev	el 3	Total

version: 2.0

			A	В	A	В	
Graft versus host disease	Total no death						0
	Total deaths						0

Add other serious adverse reaction(s)

Total nu	mber	of	Serious	Adverses	Reactions	for	this	type	of	blood
compone	ent:									

0

Comments:

version: 2.0

1,849

Annual notification for serious adverse reaction(s) related to*:

Cryoprecipitates

Number of units issued *:

4,276

Total number of units issued with a given number of blood components (See point 2.2.1 of the Common approach version 2)

Number of recipients transfused (if available):

Total number of recipients transfused with a given number of blood components. (See section 2.2.2 of the common approach version 2)

Number of units tranfused (if available):

Total number of blood components (units) transfused over the

A: Number of confirmed reports of serious adverse reactions related to blood or blood components which are not attributable to the quality and

reporting period.

(See section 2.2.3 of the common approach version 2)

safety of the blood/blood component

B: Number of confirmed reports of serious adverse reactions related to blood or blood components which are attributable to the quality and safety of the blood/blood component.

(See section 2.3 of the common approach version 2)

Imputability level aft Serious Adver	er confirmation of se Reaction(s)	the	not assessable	Level 0	Level 1	Lev	el 2	Lev	el 3	Total
						Α	В	Α	В	
Immunological Haemolysis	Due to ABO incompatibility	Total no death								0
		Total deaths								0
	Due to other allo- antibody	Total no death								0
		Total deaths								0
			not assessable	Level 0	Level 1	Lev	el 2	Lev	el 3	Total
						A	В	A	В	
Non-immunological Haemolysis		Total no death								0
		Total deaths								0
			not assessable	Level 0	Level 1	Lev	el 2	Lev	el 3	Total
						Α	В	Α	В	
Transfusion-transmitted bacterial infection		Total no death								0
		Total deaths								0

version: 2.0

			not assessable	Level 0	Level 1	Lev	Level 2		el 3	Total
						Α	В	Α	В	
Anaphylaxis/hypersensitivity		Total no death								0
		Total deaths								0
d		not assessable	Level 0	Level 1	Level 2		Level		Total	
						Α	В	Α	В	
Transfusion related acute lung injury		Total no death								0
		Total deaths								0
			not assessable	Level 0	Level 1	Lev	el 2	Lev	el 3	Total
						Α	В	Α	В	
Transfusion-transmitted viral infection	HBV	Total no death								0
		Total deaths								0
	HCV	Total no death								0
		Total deaths								0
	HIV-1/2	Total no death								0
		Total deaths								0

Add other type of Transfusion-transmitted viral infection

	c			Level 0	Level 1	1 Level 2		Leve	el 3	Total
						Α	В	Α	В	
Transfusion-transmitted parasitical infection		Total no death								0
		Total deaths								0

			not assessable	Level 0	Level 1	Lev	el 2	Lev	Total	
						Α	В	A	В	
Post-transfusion purpura		Total no death								0
		Total deaths								0
		not assessable	Level 0	Level 1	Lev	el 2	Lev	el 3	Total	

version: 2.0

			A	В	Α	В	
Graft versus host disease	Total no death						0
	Total deaths						0

Add other serious adverse reaction(s)

Total	number	of	Serious	Adverses	Reactions	for	this	type o	f blood
compo	onent :								

0

Comments:

version: 2.0

Annual notification for serious adverse reaction(s) related to Granulocytes	x
Number of units issued * :	Total number of units issued with a given number of blood components (See point 2.2.1 of the Common approach version 2)
Number of recipients transfused (if available): 1	Total number of units issued with a given number of blood components (See point 2.2.1 of the Common approach version 2) transfused (if available): Total number of recipients transfused with a given number of blood components. (See section 2.2.2 of the common approach version 2)
Number of units tranfused (if available):	

A: Number of confirmed reports of serious adverse reactions related to blood or blood components which are not attributable to the quality and safety of the blood/blood component

B: Number of confirmed reports of serious adverse reactions related to blood or blood components which are attributable to the quality and safety of the blood/blood component.

(See section 2.3 of the common approach version 2)

Imputability level aft Serious Adver	er confirmation of se Reaction(s)	the	not assessable	Level 0	Level 1	Level 2		Lev	rel 3	Total
						Α	В	Α	В	
Immunological Haemolysis	Due to ABO incompatibility	Total no death								0
		Total deaths								0
	Due to other allo- antibody	Total no death								0
		Total deaths								0
			not assessable	Level 0	Level 1	Level 2		Level 3		Total
						A	В	A	В	
Non-immunological Haemolysis		Total no death								0
		Total deaths								0
		not assessable	Level 0	Level 1	Lev	el 2	Lev	rel 3	Total	
						Α	В	A	В	
Transfusion-transmitted bacterial infection		Total no death								0
		Total deaths								0

version: 2.0

			not assessable	Level 0	Level 1	Lev	el 2	Level 3		Total
						Α	В	Α	В	
Anaphylaxis/hypersensitivity		Total no death								0
		Total deaths								0
	a		not assessable	Level 0	Level 1	Level 2		? Level		Total
						Α	В	Α	В	
Transfusion related acute lung injury		Total no death								0
		Total deaths								0
			not assessable	Level 0	Level 1	Level 2		Level 3		Total
						Α	В	Α	В	
Transfusion-transmitted viral infection	HBV	Total no death								0
		Total deaths								0
	HCV	Total no death								0
		Total deaths								0
	HIV-1/2	Total no death								0
		Total deaths								0

Add other type of Transfusion-transmitted viral infection

		not assessable	Level 0	Level 1	Lev	el 2	Leve	el 3	Total
					A	В	A	В	
Transfusion-transmitted parasitical infection	Total no death								0
	Total deaths								0

		not assessable	Level 0	Level 1	Level 2		Lev	el 3	Total
					Α	В	A	В	
Post-transfusion purpura	Total no death								0
	Total deaths								0
		not assessable	Level 0	Level 1	Level 2 Level 3		Total		

version: 2.0

				Α	В	Α	В		
Graft versus host disease		Total no death						0	
		Total deaths						0	

Add other serious adverse reaction(s)

Total number of Serious	Adverses	Reactions	for	this	type	of	blood
component :							

0

Comments:

version · 20

Annual notification for serious adverse reaction(s) rela Plasma SD	ated to*:
Number of units issued * :	Total number of units issued with a given number of blood components (See point 2.2.1 of the Common approach version 2)
Number of recipients transfused (if available): 5,262	Total number of recipients transfused with a given number of blood components. (See section 2.2.2 of the common approach version 2)
Number of units tranfused (if available): 45,720	Total number of blood components (units) transfused over the reporting period. (See section 2.2.3 of the common approach version 2)

A: Number of confirmed reports of serious adverse reactions related to blood or blood components which are not attributable to the quality and safety of the blood/blood component

B: Number of confirmed reports of serious adverse reactions related to blood or blood components which are attributable to the quality and safety of the blood/blood component.

(See section 2.3 of the common approach version 2)

Imputability level aft Serious Adver	er confirmation of se Reaction(s)	the	not assessable	Level 0	Level 1	Lev	el 2	Lev	el 3	Total
						Α	В	Α	В	
Immunological Haemolysis	Due to ABO incompatibility	Total no death								0
		Total deaths								0
	Due to other allo- antibody	Total no death								0
		Total deaths								0
	not assessable	Level 0	Level 1	Level 2		Level 3		Total		
						A	В	A	В	
Non-immunological Haemolysis	Non-immunological Haemolysis									0
		Total deaths								0
			not assessable	Level 0	Level 1	Lev	el 2	Lev	el 3	Total
						Α	В	Α	В	
Transfusion-transmitted bacterial infection		Total no death								0
		Total deaths								0

version: 2.0

			not assessable	Level 0	Level 1	Lev	el 2	Lev	el 3	Total
						Α	В	Α	В	
Anaphylaxis/hypersensitivity		Total no death								0
		Total deaths								0
			not assessable	Level 0	Level 1	Lev	el 2	Lev	el 3	Total
						Α	В	Α	В	
Transfusion related acute lung injury		Total no death								0
		Total deaths								0
			not assessable	Level 0	Level 1	Lev	el 2	Lev	el 3	Total
						Α	В	Α	В	
Transfusion-transmitted viral infection	HBV	Total no death								0
		Total deaths								0
	HCV	Total no death								0
		Total deaths								0
	HIV-1/2	Total no death								0
		Total deaths								0

Add other type of Transfusion-transmitted viral infection

		not assessable	Level 0	Level 1	Lev	el 2	Lev	el 3	Total
					A	В	Α	В	
Transfusion-transmitted parasitical infection	Total no death								0
	Total deaths								0

			not assessable	Level 0	Level 1	Level 2		Lev	Total	
						Α	В	A	В	
Post-transfusion purpura		Total no death								0
		Total deaths								0
			not assessable	Level 0	Level 1	Lev	el 2	Lev	el 3	Total

version: 2.0

			Α	В	Α	В	
Graft versus host disease	Total no death						0
	Total deaths						0

Add other serious adverse reaction(s)

Total	number	of	Serious	Adverses	Reactions	for	this	type o	f blood
compo	onent :								

0

Comments:

version: 2.0

Add a new annual notification of serious adverse reaction(s) for another blood component

version: 2.0

Annual notification for Serious Adverse EVENT(S)

Total number of units processed : (See section 3.1 of the Common approach version 2)

Specific	ation	Ad	ditional details (if available)	Quantity	
					>
		Total			
			Add a new specification		

Add a new category of serious adverse event(s)

version: 2.0

General comments on this Annual Notification :								